{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:49:59Z","timestamp":1789235399009,"version":"build-2803163510"},"reference-count":57,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,16]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>The inert ingredients in Opana ER tablets can elicit TMA in the setting of IV abuse and stems from the impact of HMW PEO.<\/jats:p>","DOI":"10.1182\/blood-2016-08-736579","type":"journal-article","created":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T03:30:34Z","timestamp":1479526234000},"page":"896-905","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-9919","authenticated-orcid":false,"given":"Ryan","family":"Hunt","sequence":"first","affiliation":[{"name":"Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-9297","authenticated-orcid":false,"given":"Ayla","family":"Yalamanoglu","sequence":"additional","affiliation":[{"name":"Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tumlin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Tennessee College of Medicine at Chattanooga, Chattanooga, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Schiller","sequence":"additional","affiliation":[{"name":"Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyen","family":"Baek","sequence":"additional","affiliation":[{"name":"Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Department of Pathology, George Washington School of Medicine and Health Sciences, Washington, DC;"},{"name":"Department of Coagulation, Quest Diagnostics\/Nichols Institute, Chantilly, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Miller","sequence":"additional","affiliation":[{"name":"Section on Hematology and Oncology, Department of Internal Medicine,"},{"name":"Section on Pulmonary, Critical Care, Allergy and Immunology, and"},{"name":"Section on Critical Care Medicine, Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Buehler","sequence":"additional","affiliation":[{"name":"Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chava","family":"Kimchi-Sarfaty","sequence":"additional","affiliation":[{"name":"Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"50-51","key":"2019111904160279600_B1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths--United States, 2000-2014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2019111904160279600_B2","first-page":"1","article-title":"Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse\u2013Tennessee, 2012","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2019111904160279600_B3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ajem.2014.01.058","article-title":"Resurgence of intravenous Opana as a cause of secondary thrombotic thrombocytopenic purpura","volume":"32","author":"Rane","year":"2014","journal-title":"Am J Emerg Med"},{"issue":"7","key":"2019111904160279600_B4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.23720","article-title":"Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange","volume":"89","author":"Miller","year":"2014","journal-title":"Am J Hematol"},{"issue":"20","key":"2019111904160279600_B5","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2013-05-503904","article-title":"Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndrome","volume":"122","author":"Amjad","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111904160279600_B6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamaophthalmol.2014.324","article-title":"Diffuse retinal ischemia following intravenous crushed oxymorphone abuse","volume":"132","author":"Shah","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"2019111904160279600_B7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.ajkd.2014.01.015","article-title":"Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases","volume":"63","author":"Ambruzs","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2019111904160279600_B8","first-page":"40","article-title":"Thrombotic microangiopathy associated with Opana ER intravenous abuse: a case report","volume":"64","author":"Jabr","year":"2016","journal-title":"J Med Liban"},{"issue":"16","key":"2019111904160279600_B9","first-page":"443","article-title":"Community outbreak of HIV infection linked to injection drug use of oxymorphone--Indiana, 2015","volume":"64","author":"Conrad","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"2019111904160279600_B10","first-page":"1847","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904160279600_B11","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"Fujikawa","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2019111904160279600_B12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","article-title":"Partial amino acid sequence of purified von Willebrand factor-cleaving protease","volume":"98","author":"Gerritsen","year":"2001","journal-title":"Blood"},{"issue":"6855","key":"2019111904160279600_B13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"issue":"23","key":"2019111904160279600_B14","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"2019111904160279600_B15","unstructured":"US Food and Drug Administration. FDA Statement: Original Opana ER Relisting Determination. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm351357.htm. Accessed 7 July 2016."},{"issue":"2","key":"2019111904160279600_B16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0041-008X(70)90016-5","article-title":"Experimental toxicity of a high molecular weight poly(ethylene oxide)","volume":"16","author":"Smyth","year":"1970","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"2019111904160279600_B17","first-page":"61","article-title":"[Myelotoxicity of high-molecular-weight poly(ethylene oxide)]","volume":"67","author":"Karpova","year":"2004","journal-title":"Eksp Klin Farmakol"},{"issue":"2","key":"2019111904160279600_B18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/toxsci\/kfs109","article-title":"Down selection of polymerized bovine hemoglobins for use as oxygen releasing therapeutics in a guinea pig model","volume":"127","author":"Baek","year":"2012","journal-title":"Toxicol Sci"},{"key":"2019111904160279600_B19","doi-asserted-by":"crossref","first-page":"e2064","DOI":"10.1038\/cddis.2015.392","article-title":"Hemoglobinuria-related acute kidney injury is driven by intrarenal oxidative reactions triggering a heme toxicity response","volume":"7","author":"Deuel","year":"2016","journal-title":"Cell Death Dis"},{"key":"2019111904160279600_B20","author":"Hein"},{"issue":"3","key":"2019111904160279600_B21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood.V74.3.978.978","article-title":"Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome","volume":"74","author":"Mannucci","year":"1989","journal-title":"Blood"},{"issue":"8","key":"2019111904160279600_B22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.V83.8.2171.2171","article-title":"Shear stress enhances the proteolysis of von Willebrand factor in normal plasma","volume":"83","author":"Tsai","year":"1994","journal-title":"Blood"},{"issue":"3","key":"2019111904160279600_B23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4065\/mcp.2010.0309","article-title":"Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy","volume":"86","author":"Blackshear","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2019111904160279600_B24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.athoracsur.2005.07.074","article-title":"Acquired and reversible von Willebrand disease with high shear stress aortic valve stenosis","volume":"81","author":"Yoshida","year":"2006","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2019111904160279600_B25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111904160279600_B26","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V90.4.1558.1558_1558_1564","article-title":"Fluid shear stress modulates von Willebrand factor release from human vascular endothelium","volume":"90","author":"Galbusera","year":"1997","journal-title":"Blood"},{"issue":"5","key":"2019111904160279600_B27","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V71.5.1366.bloodjournal7151366","article-title":"Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin","volume":"71","author":"Moake","year":"1988","journal-title":"Blood"},{"issue":"6","key":"2019111904160279600_B28","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation","volume":"78","author":"Moake","year":"1986","journal-title":"J Clin Invest"},{"key":"2019111904160279600_B29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/00365510802150158","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease","volume":"241","author":"Devarajan","year":"2008","journal-title":"Scand J Clin Lab Invest Suppl"},{"issue":"3","key":"2019111904160279600_B30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2215\/CJN.04010907","article-title":"Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study","volume":"3","author":"Bennett","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2019111904160279600_B31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2019111904160279600_B32","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMra042823","article-title":"Bacterial infections in drug users","volume":"353","author":"Gordon","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111904160279600_B33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-0404.1988.tb03650.x","article-title":"Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins","volume":"78","author":"Thorlacius","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"2019111904160279600_B34","doi-asserted-by":"crossref","first-page":"11256","DOI":"10.1038\/srep11256","article-title":"Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models","volume":"5","author":"Cui","year":"2015","journal-title":"Sci Rep"},{"issue":"6","key":"2019111904160279600_B35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/BF01049712","article-title":"Effect of drag-reducing polymers on the structure of the stagnant zones and eddies in models of constricted and branching blood vessels","volume":"25","author":"Kameneva","year":"1990","journal-title":"Fluid Dynamics"},{"key":"2019111904160279600_B36","first-page":"620","article-title":"Influence of polyethylene oxide on the capilllary blood flow in the diabetic rat","volume":"32","author":"Golub","year":"1987","journal-title":"Sov Phys Dokl"},{"key":"2019111904160279600_B37","first-page":"702","article-title":"Effect of high molecular weight compounds dissolved in blood on hemodynamics","volume":"21","author":"Grigorian","year":"1976","journal-title":"Sov Phys Dokl"},{"issue":"19","key":"2019111904160279600_B38","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/eurheartj\/ehl165","article-title":"A novel hydrodynamic approach to the treatment of coronary artery disease","volume":"27","author":"Pacella","year":"2006","journal-title":"Eur Heart J"},{"issue":"4","key":"2019111904160279600_B39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/BIR-2009-0543","article-title":"Drag reducing polymers improve tissue perfusion via modification of the RBC traffic in microvessels","volume":"46","author":"Marhefka","year":"2009","journal-title":"Biorheology"},{"issue":"11","key":"2019111904160279600_B40","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.freeradbiomed.2011.02.011","article-title":"Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response","volume":"50","author":"Billings","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"2019111904160279600_B41","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1093\/ndt\/gfr391","article-title":"Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression","volume":"26","author":"Ballar\u00edn","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2019111904160279600_B42","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1053\/j.ajkd.2010.03.025","article-title":"Hemolysis and acute kidney failure","volume":"56","author":"Qian","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2019111904160279600_B43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ki.2010.24","article-title":"Hemolysis is associated with acute kidney injury during major aortic surgery","volume":"77","author":"Vermeulen Windsant","year":"2010","journal-title":"Kidney Int"},{"issue":"5","key":"2019111904160279600_B44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V32.5.811.811","article-title":"Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases","volume":"32","author":"Muller-Eberhard","year":"1968","journal-title":"Blood"},{"issue":"8","key":"2019111904160279600_B45","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2012-11-451229","article-title":"Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins","volume":"121","author":"Schaer","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111904160279600_B46","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/toxins6041244","article-title":"Extracellular Hb enhances cardiac toxicity in endotoxemic guinea pigs: protective role of haptoglobin","volume":"6","author":"Baek","year":"2014","journal-title":"Toxins (Basel)"},{"issue":"11","key":"2019111904160279600_B47","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/cdd.2013.113","article-title":"Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damage","volume":"20","author":"Schaer","year":"2013","journal-title":"Cell Death Differ"},{"issue":"4","key":"2019111904160279600_B48","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1172\/JCI59770","article-title":"Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy","volume":"122","author":"Baek","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111904160279600_B49","doi-asserted-by":"crossref","first-page":"a013433","DOI":"10.1101\/cshperspect.a013433","article-title":"Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies","volume":"3","author":"Schaer","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2019111904160279600_B50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fphys.2014.00415","article-title":"Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development","volume":"5","author":"Schaer","year":"2014","journal-title":"Front Physiol"},{"issue":"10","key":"2019111904160279600_B51","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201510-2058OC","article-title":"Haptoglobin preserves vascular nitric oxide signaling during hemolysis","volume":"193","author":"Schaer","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2019111904160279600_B52","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1002\/app.1971.070151207","article-title":"Degradation of drag-reducing polymers","volume":"15","author":"Fisher","year":"1971","journal-title":"J Appl Polym Sci"},{"issue":"5","key":"2019111904160279600_B53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3233\/BIR-2008-0511","article-title":"Mechanical degradation of drag reducing polymers in suspensions of blood cells and rigid particles","volume":"45","author":"Marhefka","year":"2008","journal-title":"Biorheology"},{"issue":"15","key":"2019111904160279600_B54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJMsr1601307","article-title":"A proactive response to prescription opioid abuse","volume":"374","author":"Califf","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904160279600_B55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5694\/mja14.01125","article-title":"Intravenous oxycontin-associated thrombotic microangiopathy treated successfully without plasma exchange","volume":"202","author":"Tate","year":"2015","journal-title":"Med J Aust"},{"issue":"4","key":"2019111904160279600_B56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ckj\/sfw039","article-title":"Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone","volume":"9","author":"Nataatmadja","year":"2016","journal-title":"Clin Kidney J"},{"key":"2019111904160279600_B57","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7517-7-24","article-title":"Route of administration for illicit prescription opioids: a comparison of rural and urban drug users","volume":"7","author":"Young","year":"2010","journal-title":"Harm Reduct J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/7\/896\/1402270\/blood736579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/7\/896\/1402270\/blood736579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T11:29:13Z","timestamp":1601206153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/7\/896\/36204\/A-mechanistic-investigation-of-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,2,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-736579","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]}}}